Mometasone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Mometasone: From Corticosteroid Therapy to Primary Cutaneous T-Cell Lymphoma
One-Sentence Summary
Mometasone furoate is a topical/intranasal/inhaled corticosteroid; a confirmed original-indication record was not available in this evidence pack. The TxGNN model predicts potential activity in primary cutaneous T-cell lymphoma (CTCL), but this direction is currently supported only by 2 indirect case-report publications and no clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in evidence pack (no license/indication text available); mometasone furoate is generally used as a topical, intranasal, or inhaled corticosteroid for allergic/inflammatory conditions |
| Predicted New Indication | Primary cutaneous T-cell lymphoma |
| TxGNN Prediction Score | 99.36% |
| Evidence Level | L4 (mechanistic/indirect case-report evidence only) |
| South Africa Market Status | Not Marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data for mometasone is not available in this evidence pack (data gap). Based on known pharmacology, mometasone furoate is a synthetic glucocorticoid receptor agonist with anti-inflammatory and immunosuppressive activity, formulated for topical, intranasal, or inhaled use.
The repurposing rationale for CTCL rests on this general corticosteroid mechanism: glucocorticoid receptor agonism could theoretically suppress cutaneous T-cell infiltration and neoplastic lymphocyte proliferation. Topical corticosteroids (including mometasone furoate) are already a recognized skin-directed treatment option for early-stage mycosis fungoides/CTCL, which lends the prediction some mechanistic plausibility.
However, none of the literature identified in this evidence set studies mometasone as a treatment for CTCL directly — the supporting evidence is indirect inference from corticosteroid class effects and adjacent disease contexts, not disease-specific data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 40821495 | 2025 | Case Report | Proceedings (Baylor University Medical Center) | Cutaneous pseudolymphoma (a T-cell lymphoproliferative process that mimics cutaneous lymphoma) failed to respond to mometasone and tacrolimus before responding to tapinarof — mometasone use noted, but as a failed prior therapy, not as evidence of efficacy |
| 25442255 | 2015 | Case Report/Case Series | Journal of Cutaneous Pathology | Describes a case of childhood CD8+CD56+ mycosis fungoides (a form of CTCL); abstract does not report mometasone treatment or outcome — relevance is disease-context only |
Both publications are Tier 3 case reports and provide only indirect support; neither demonstrates mometasone efficacy in CTCL.
South Africa Market Information
Mometasone currently has no SAHPRA registration on record (South Africa market status: Not Marketed; 0 licenses in the evidence pack).
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Note: This evidence pack flags a Blocking data gap (DG001) — TFDA/SAHPRA label warnings and contraindications have not yet been retrieved, which prevents a formal safety (S1) assessment for this candidate.
Conclusion and Next Steps
Decision: Hold
Rationale:
- Evidence is limited to two indirect case reports (evidence level L4) with no clinical trials and no direct study of mometasone in CTCL; the drug is also not currently registered or marketed in South Africa, and a blocking safety data gap prevents formal risk assessment.
To proceed, the following is needed:
- SAHPRA/TFDA-approved Professional Information (warnings, contraindications) to resolve the blocking data gap (DG001)
- Confirmed mechanism of action data from DrugBank (DG002)
- Direct clinical or preclinical studies evaluating mometasone (or class-equivalent topical corticosteroids) specifically in CTCL/mycosis fungoides
- Clarification of original approved indication(s) and dosage forms/routes to assess route compatibility with the proposed dermatologic use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.